The role of TIMP-1 as a biomarker has in recent years become increasingly interesting in relation to the second line treatment of glioblastomas consisting of the vascular endothelial growth factor antibody bevazicumab, administered in combination with the chemotherapeutic drug irinotecan [38–41]. Here, VEGFA is linked to glioblastoma.